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ABSTRACT
The Center for Cell Research (CCR) is a NASA Center for the Commercial Development of Space
which has as its main goal encouraging industry-driven biomedical/biotechnology space projects.
Space Station Freedom (SSF) will provide long duration, crew-tended microgravity environments
which will enhance the opportunities for commercial biomedical/biotechnology projects in
bioseparations and physiological testing.
The CCR bioseparations program, known as USCEPS (for United States Commercial Electrophore-
sis Program in Space), is developing access for American industry to continuous-flow electrophoresis
aboard SSF. In space, considerable scale-up of continuous free-flow electrophoresis is possible for
cells, subcellular particles, proteins, growth factors and other biological products. The lack of
sedimination and buoyancy-driven convection flow enhances purity of separations and the amount
of material processed/time.
Through the CCR's physiological testing program, commercial organizations will have access
aboard SSF to physiological systems experiments (PSEs); the Penn State Biomodule; and
telemicroscopy. Physiological systems experiments involve the use of live animals for pharmaceu-
tical product testing and discovery research. The Penn State Biomodule is a computer-controlled
minilab useful for projects involving live cells or tissues and macromolecular assembly studies,
including protein crystallization. Telemicroscopy will enable staff on Earth to manipulate and
monitor microscopic specimens on SSF for product development and discovery research or for
medical diagnosis of astronaut health problems.
Space-based product processing, testing, development and discovery research using USCEPS and
CCR's physiological testing program offer new routes to improved health on Earth. Direct crew
involvement in biomedical/biotechnology projects aboard SSF will enable better experimental
outcomes. The current data base shows that there is reason for considerable optimism regarding what
the CCDS program and the biomedical/biotechnology industry can expect to gain from a permanent
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NASA CODE C MISSION
"...TO SEEK AND ENCOURAGE, TO THE MAXIMUM EXTENT POSSIBLE,
THE FULLEST COMMERCIAL USE OF SPACE."





CCR COMMERCIAL PARTNER PROGRAM
FOR
PRODUCT TESTING AND INDUSTRY-DRIVEN DISCOVERY RESEARCH
1. FLIGHT ACCESS
2. EXPERIMENT PLANNING AND POST FLIGHT ANALYSIS
3. PAYLOAD PLANNING, INTEGRATION, MISSION MANAGEMENT
4. FLIGHT CERTIFIED HARDWARE
5. INTELLECTUAL PROPERTY AGREEMENTS
6. SUPPORT
PENNSTATE
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SPACE BIOTECHNOLOGY: OPPORTUNITIES FOR







EXPOSING ANIMALS AND MAN TO SURPRISINGLY SHORT PERIODS OF
MICROGRAVITY CAUSES PHYSIOLOGICAL CHANGES WHICH RESEMBLE
HUMAN DISEASES, SUCH AS OSTEOPOROSlS, MUSCLE WASTAGE,
ABNORMAL HORMONE SECRETION, LOWERED IMMUNE FUNCTION AND





SOUNDING ROCKETS U.S. SPACE SHUTTLE/RUSSIAN SATELLITE SKYLAB-MIR
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SINGLE CELLS IN REDUCED GRAVITY
• BACTERIAL PROLIFERATE MORE RAPIDLY
• BACTERIAL CONJUNCTION RATE INCREASED
• INCREASED RESISTANCE OF E. COLI TO ANTIBIOTICS
• REDUCTION IN SPORULATION RATE
• 4 FOLD INCREASE IN PROLIFERATION OF PARAMECIUM TETRAURELIA
• VIRTUAL TOTAL SUPPRESSION OF BLASTOGENIC RESPONSE IN
T-LYMPHOCYTES EXPOSED TO CON-A
• RAT PITUITARY CELLS SHOW 20 FOLD SUPPRESSION OF BASAL GH
RELEASE POSTFLIGHT
• 5 FOLD INCREASE IN GAMMA-INTERFERON PRODUCTION IN pG
• INCREASE IN MEMBRANE FUSION EVENTS (HYBRIDOMA)
• DECREASED GLUCOSE CONSUMPTION IN HUMAN EMBRYONIC LUNG
FIBROBLASTS
PENNSTATE
lJ THE CENTER FORCELLRESEARCH
FIRST COMMERCIAL PHYSIOLOGICAL TESTING
EXPERIMENT IN SPACE
GENENTECH, INC. AND CENTER FOR CELL RESEARCH
SPACE SHUTTLE DISCOVERY OCTOBER 6, 1990
COMMERCIAL GOAL: PROPRIETARY
EXPERIMENT MEASURED THE EFFECT OF A NUMBER OF PROTEINS
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HARDWARE
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CONSORT SOUNDING ROCKET MISSIONS
DEMONSTRATE VERSATILITY OF BIOMODULE
ABOARD CONSORT 4, THE PENN STATE BIOMODULE WAS USED SUCCESSFULLY
FOR THE FIRST TIME TO STUDY MICROGRAVITY EFFECTS ON MAMMALIAN CELLS,
PLANT TISSUES AND PROTEIN CRYSTALS EXTENDING ITS UTILITY TO THREE
MORE CLASSES OF BIOLOGICAL MATERIALS OF COMMERCIAL INTEREST.
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TELEMICROSCOPY
THE CORABI/CCR TELEMICROSCOPY PROJECT WILL PROVIDE THE COMMERCIAL
BIOMEDICAL/BIOTECHNOLOGY COMMUNITY WITH THE OPPORTUNITY TO
STUDY MICROSCOPIC SPECIMENS ABOARD SPACE STATION FREEDOM FROM
THE GROUND.
APPLICATIONS; tvIONITOR PRODUCT PROCESSING, PRODUCTION,
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CONCLUSION
SPACE-BASED PRODUCT PROCESSING, TESTING, DEVELOPMENT AND
DISCOVERY RESEARCH USING USCEPS AND CCR'S PHYSIOLOGICAL TESTING
PROGRAM OFFER NEW ROUTES TO IMPROVED HEALTH ON EARTH.
THE CCR AND SSF WILL HELP AMERICAN INDUSTRY TO TAKE THOSE ROUTES
AND TO USE MiCROGRAVlTY AS AN ENABLING FORCE TO ACHIEVE PRODUCT-
ORIENTED GOALS.
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